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Hepatocellular carcinoma (HCC) is one of the most common can-
cers worldwide. Most HCCs develop in cirrhotic livers. Alcoholic 
liver disease, chronic hepatitis B and chronic hepatitis C are 
the most common underlying liver diseases. Hepatitis C virus 
(HCV)-specific mechanisms that contribute to HCC are presently 
unknown. Transgenic expression of HCV proteins in the mouse 
liver induces an overexpression of the protein phosphatase 2A cat-
alytic subunit (PP2Ac). We have previously reported that HCV-
induced PP2Ac overexpression modulates histone methylation 
and acetylation and inhibits DNA damage repair. In this study, we 
analyze tumor formation and gene expression using HCV trans-
genic mice that overexpress PP2Ac and liver tissues from patients 
with HCC. We demonstrate that PP2Ac overexpression interferes 
with p53-induced apoptosis. Injection of the carcinogen, diethyl-
nitrosamine, induced significantly more and larger liver tumors 
in HCV transgenic mice that overexpress PP2Ac compared with 
control mice. In human liver biopsies from patients with HCC, 
PP2Ac expression was significantly higher in HCC tissue com-
pared with non-tumorous liver tissue from the same patients. Our 
findings demonstrate an important role of PP2Ac overexpression 
in liver carcinogenesis and provide insights into the molecular 
pathogenesis of HCV-induced HCC.
Introduction
Hepatocellular carcinoma (HCC) is the most prevalent primary liver 
cancer and a major cause of cancer mortality worldwide. The major 
risk factor for HCC is chronic hepatitis B, followed by chronic hepa-
titis C (CHC) and chronic alcoholic liver disease (1). In Europe, most 
HCCs occur in cirrhosis, and it is well established that cirrhosis is a 
major risk factor for HCC independent of the underlying liver dis-
ease. However, in the context of chronic hepatitis B or CHC, HCC can 
develop also in non-cirrhotic livers. Virus-induced chronic inflamma-
tion can impair DNA damaged repair, rendering cells more suscepti-
ble to spontaneous or mutagen-induced alterations (2). There are also 
experimental evidences of the oncogenic potential of hepatitis C virus 
(HCV) proteins such as HCV core. For instance, it has been reported 
that HCV core transgenic mice develop hepatic steatosis and HCC at 
the age of 16–19 months (3).
We have reported previously that HCV infection induces an upreg-
ulation of protein phosphatase 2A (PP2A) catalytic subunit through 
an endoplasmic reticulum stress response pathway (4,5). PP2A is a 
heterotrimeric protein phosphatase consisting of a 36 kD catalytic 
C subunit (PP2Ac), a 65 kD structural A  subunit and a variable 
regulatory B subunit. This phosphatase is widely expressed in all cell 
types and is involved in the posttranslational control of signaling pro-
teins by performing reversible phosphorylation (6). In recent work, 
we observed that HCV-induced PP2Ac overexpression in cells leads 
to an inhibition of histone H4 posttranslational modifications and 
impairs the DNA repair machinery (7). We also found that cotrans-
fection of c-myc and HA-PP2Ac plasmids into NIH3T3 cells sig-
nificantly increased c-myc-induced anchorage-independent growth. 
These data suggested that PP2Ac overexpression may contribute to 
hepatocellular carcinogenesis in the context of CHC.
Cells are constantly exposed to DNA damage. In order to pre-
vent the propagation of mutations, cells have evolved systems that 
sense DNA damage and interrupt the cell cycle to allow repair of 
damaged DNA. If DNA damage is too severe and irreparable, cells 
undergo apoptosis (8). DNA damage is a hallmark of cancer cells. 
DNA damage repair is often ineffective and proapoptotic pathways 
are non-functional in many cancer types, resulting in an accumula-
tion of mutations during cancer evolution (9). PP2A is of particular 
interest in the control of apoptotic networks because of its predomi-
nant tumor-suppressive characteristics (10). However, some reports 
have shown that particular PP2A complexes can counterbalance the 
apoptotic cell death program as well. Indeed, it has been described 
that cyclin G associates with PP2A holoenzyme containing B’ subu-
nits and directs the phosphatase complex to the murine double minute 
2 (Mdm2), where PP2A dephosphorylates Mdm2 on threonine 216, 
leading to a negative regulation of p53 apoptotic function (11).
The tumor suppressor protein p53 can initiate cell cycle arrest, DNA 
repair and apoptosis (12,13). In resting cells, constant degradation 
through the proteasome pathway maintains low expression levels of 
p53. Upon DNA damage, p53 is stabilized and accumulated (14). This 
stabilization results from phosphorylation of p53 on serine 15 within 
the transactivation domain, inhibiting the association to Mdm2, thereby 
preventing p53 ubiquitination and proteasomal degradation (15). 
Several functions of p53 are also regulated by phosphorylation (16,17). 
For instance, phosphorylation of p53 on serine 37 and 46 is associated 
with induction of transcriptional activity and apoptosis (18,19). p53 is 
frequently found to be mutated in human cancer (20,21), and malig-
nancies that retain a wild-type p53 gene usually acquire other impair-
ments that affect p53 function (22), suggesting that p53 inactivation is 
a common step in most human cancers development.
In this study, we investigated p53 modifications and apoptotic 
pathways in PP2Ac-overexpressing cells and HCVcc-infected cells. 
We show that PP2Ac overexpression reduces p53 phosphorylation in 
response to DNA-damaging agents. Consequently, expression of p53 
proapoptotic genes is reduced, and apoptosis is inhibited. HCV trans-
genic mice that overexpress PP2Ac were more susceptible to diethyl-
nitrosamine (DEN) and had more and larger liver tumors. In human 
liver biopsies from patients with CHC and HCC, we found an overex-
pression of PP2Ac in tumor tissue and observed a significant negative 
correlation between PP2Ac and PUMA/Noxa expression.
Materials and methods
Cells and reagents
UHCV57.3, HA-PP2Ac and short-hairpin small interfering RNA PP2Aca 
cells were described previously (4,7,23). Etoposide and DEN were purchased 
from Sigma–Aldrich (Fluka Chemie GmbH, Buchs, Switzerland). Etopophos 
was obtained from Bristol-Myers Squibb SA (Baar, Switzerland). Anti-
HCV core (clone C7-50) was from ABR Affinity Bioreagents (Lucerna 
Chem AG, Lucerne, Switzerland). Anti-Caspase-9, cleaved Caspase-3, 
pSer15p53, pSer37p53, pSer18p53 and pSer46p53 were from Cell Signaling 
(Bioconcept, Allschwil, Switzerland). Anti-PP2Ac was from Millipore AG 
(Zug, Switzerland). Anti-p53 was from Santa Cruz Biotechnology (LabForce 
AG, Nunningen, Switzerland).
Abbreviations: CHC, chronic hepatitis C; CREB, cyclic adenosine 
monophosphate response element-binding protein; DEN, diethylnitrosamine; 
HCC, hepatocellular carcinoma; HCV, hepatitis C virus; PP2Ac, protein phos-
phatase 2A catalytic subunit; SEM, standard error of the mean.
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HCV particles production and infection of Huh7.5.1 cells
RNA preparation and electroporation were done as described (24). Huh7.5.1 
cells were infected with HCV particles at multiplicity of infection of 1 for 
3 days.
Animals and experimental design
HCV transgenic mice (B6HCV) were described previously (25). The DEN 
injection study was performed in two groups of mice: C57BL6 injected with 
DEN (5 µg/g) (n = 22) and B6HCV injected with DEN (5 µg/g) (n = 19). DEN 
was injected once intraperitoneally to mice at 2 weeks of age. The animals 
were euthanized 40 weeks after injection by CO2 inhalation. The resected 
liver lobes were immediately frozen in liquid nitrogen and kept at −70°C. The 
Etopophos injection study was performed in four groups of mice at 8 weeks of 
age: C57BL6, no injection (n = 2); C57BL6 injected with Etopophos (100 mg/
m2) (n = 2); B6HCV, no injection (n = 2) and B6HCV injected with Etopophos 
(100 mg/m2) (n = 2). Etopophos was injected intraperitoneally to the mice and 
the animals were euthanized after 2 h.
Microcystin LR (Sigma–Aldrich, Fluka Chemie GmbH) injection (70 µg/
kg) was performed intraperitoneally, and the mice were euthanized after 2 h.
Protein preparation and western blotting analysis
Whole cell extracts (from cell lines and from mouse liver tissues) and 
western blot analysis were performed as described previously (7,26). 
Densitometry analysis of protein bands was performed with ImageJ soft-
ware (NIH Image).
RNA isolation, reverse transcription and SYBR–PCR
RNA isolation, reverse transcription and SYBR–PCR were done as described 
previously (7). The human primers were 5′-TCTTCCTCTGAGGCGAGCT-3′ 
and 5′-AGGTGTGTGTGTCTGAGCCC-3′ for p53AIP1; 5′-AGAGCTGGAA 
GTCGAGTGT-3′ and 5′-GCACCTTCACATTCCTCTC-3′ for Noxa; 5′-AAG 
ACCATGTGGACCTGT-3′ and 5′-GGTAGAAATCTGTCATGCTG-3′ for p21; 
5′-CCTGCCAGATTTGTGAGACAAG-3′ and 5′-CAGGAGTCCCATGATG 
AGATTG-3′ for PUMA; 5′-CCACAGCAAGTCACACATTGG-3′ and 5′-CAG 
AGCACTTGATCGCCTACAA-3′ for PP2Ac; 5′-GCTCCTCCTGTTCGACA 
GTCA-3′ and 5′-ACCTTCCCCATGGTGTCTGA-3′ for GAPDH. The mouse 
primers were 5′-ATCCGCAAGCCTGTGACTGT-3′ and 5′-TCGGGCCAGG 
GTGTTTTT-3′ for RPL19; 5′-GCCCAGCAGCACTTAGAGTC-3′ and 5′-TGT 
CGATGCTGCTCTTCTTG-3′ for PUMA; 5′-CCCAGATTGGGGACCTTA 
GT-3′ and 5′-TCCTCATCCTGCTCTTTTGC-3′ for Noxa.
Paired liver biopsies
All patients were recruited in the Hepatology Outpatient Clinic of the 
University Hospital Basel, Switzerland. All patients gave written informed 
consent to participate in this study and donated a liver biopsy specimen 
for research purposes. The study was approved by the Ethics Committee 
of Basel.
Biopsies of the tumor and non-tumorous tissue from a distal site of the liver 
were performed using coaxial technique. One biopsy specimen from each site 
was assessed by a pathologist. Biopsy specimens with at least 50% of HCC 
tissue in the tumor sample and tumor free in the control sample were used for 
the analysis.
Biopsy samples were frozen immediately after collection and stored in 
liquid nitrogen until processing. Total RNA was extracted using Qiazol 
reagent and RNAeasy Mini Kit (Qiagen) according to the manufacturer’s 
instructions. Reverse transcription and quantitative PCR were performed as 
described above.
Soft agar assay
Human hepatoma cells and human primary lung fibroblasts (kindly pro-
vided by Prof. Michael Roth) transfected with HA-PP2Ac plasmid using 
FuGene HD, according to the manufacturer’s recommendations, were cul-
tured for 7 days in a semisolid culture media, and colonies were visualized 
under light microscopy.
Caspase-9 assay
Huh7 and HA-PP2Ac cells were treated with 100 µM etoposide for 
1 h, and caspase-9 activity was measured using Caspase-Glo 9 Assay 
(Promega AG, Dübendorf, Switzerland) according to the manufacturer’s 
instructions.
In vitro dephosphorylation assay
Whole cell lysate from Huh7 cells stimulated with 100 µM etoposide for 
1 h was prepared and then incubated with or without 1 U of purified PP2A 
(Upstate, Millipore AG) at 37°C for 10 min. The reaction was then stopped by 
heating at 100°C for 5 min and then loaded on a sodium dodecyl sulfate–poly-
acrylamide gel electrophoresis. pSer15p53, pSer37p53 and pSer46p53 were 
then visualized with specific antibodies.
Cleaved caspase-3 immunofluorescence staining
Briefly, sections (10  µm) from mouse liver embedded in optimal cutting 
temperature compound were prepared and mounted onto polylysine slides 
(Thermo Fisher Scientific, Wohlen, Switzerland). Tissue sections were then 
fixed in absolute methanol (−20°C, 15 min) and then rinsed twice in phos-
phate-buffered saline before being blocked in a 2% bovine serum albumin 
and 0.2% Triton-X solution for 30 min at room temperature. Primary anti-
body incubation was performed overnight at 4°C. Slides were then rinsed 
twice in phosphate-buffered saline. Epitopes detection was performed using 
fluorescein-conjugated goat anti-rabbit (Invitrogen Molecular Probes, Eugene, 
OR). Nuclei were stained by 4′,6-diamidino-2-phenylindole, and slides 
were mounted with a water-based mounting medium (Ultramount Aqueous 
Permanent Mounting Medium; Dako, Carpinteria, CA).
Paraffin-embedded sections and hematoxylin staining
Fresh liver tissue was fixed in 4% paraformaldehyde overnight. Afterwards, 
tissue was embedded in paraffin, and the sections of 4 µm thickness were 
prepared, stained with H&E and analyzed under light microscopy. Liver 
tumors were classified according to a consensus report on murine liver 
lesions (27).
Results
PP2Ac overexpression impairs p53 phosphorylation, p53-induced 
target genes expression and p53-induced apoptosis
We have shown previously that the expression of HCV proteins in 
cells induces PP2Ac protein expression (4). To explore a potential 
role of PP2A in the regulation of p53 function, we used cells that 
allow the inducible expression of HCV proteins (UHCV57.3 cells) 
to upregulate PP2Ac and then stimulated p53 phosphorylation with 
the DNA-damaging agent etoposide. As shown in Figure  1, HCV-
mediated upregulation of PP2Ac impaired etoposide-induced p53 
phosphorylation on serine 37 and 46 (Figure  1A) and significantly 
reduced expression of the canonical p53 target genes—p53AIP1, 
Noxa, p21 and PUMA (Figure 1B). Next, we confirmed the role of 
PP2Ac in Huh7-derived cells that express a constitutive active form of 
PP2Ac (HA-PP2Ac). Compared with control Huh7 cells, etoposide-
induced phosphorylation of serine 37 and 46 was significantly inhib-
ited (Figure 1C). Accordingly, the induction of p53 target genes was 
also reduced in HA-PP2Ac (Figure 1D).
There was also a slight reduction of serine 15 phosphorylation 
in UHCV57.3 cells but not in HA-PP2Ac cells. To assess if HCV 
causes an additional inhibition of p53 phosphorylation on serine 15, 
we infected Huh7.5 cells with the cell culture infectious JC-1 clone 
of HCV. HCV-infected cells indeed had an overexpression of PP2Ac, 
and etoposide-induced phosphorylation of serine 37 and 46 was inhib-
ited (Supplementary Figure S1, available at Carcinogenesis Online). 
However, no change in serine 15 phosphorylation was observed.
We further explored the mechanism by which PP2A reduces etopo-
side-induced p53 phosphorylation using an in vitro dephosphorylation 
assay. Extracts from etoposide-treated Huh7 cells were incubated with 
purified PP2A for 10 min, followed by western blotting using antibod-
ies specific for phosphorylated serine residues on p53. There was a 
strong reduction of phosphoserine 37 and 46 but no effect on serine 15 
(Supplementary Figure S2, available at Carcinogenesis Online).
Activated p53 can eliminate tumor cells by inducing apoptosis 
through caspase-9 activation. We, therefore, measured caspase-9 
activity following etoposide treatment and found that the activity 
of caspase-9 was significantly reduced in HA-PP2Ac cells 
compared with Huh7 cells (Figure  2A), suggesting that PP2Ac 
overexpression could favor the survival of transformed cells. 
Next, we transfected human primary lung fibroblasts with the 
HA-PP2Ac plasmid and performed a cell anchorage-independent 
growth assay. In line with our data that were published previously 
(7), PP2Ac overexpression resulted in transformation of human 
primary lung fibroblasts as illustrated by colony formation in soft 
agar media (Figure 2B).
The role of PP2A in the regulation of p53 function was fur-
ther explored by silencing PP2Ac using short-hairpin small inter-
fering RNA. Knockdown of PP2Ac resulted in an increased 
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Fig. 1. PP2Ac overexpression impairs p53 phosphorylation and expression of p53 proapoptotic genes. (A) UHCV57.3 cells were derepressed by tetracycline 
for 24 h in order to induce the expression of HCV proteins. Cells were then exposed to 100 µM etoposide for 1 h, and phosphorylation of p53 on serine 15, 
37 and 46 was analyzed by western blotting. (B) Cells were stimulated with 100 µM etoposide for 24 h, and total RNA was isolated and reverse transcribed to 
complementary DNA. The expression of genes was measured by quantitative PCR (qPCR). Results are expressed as mean ± standard error of the mean (SEM) 
from three independent experiments. Statistical analysis was performed using Student’s t-test. (C) Huh7 and HA-PP2Ac cells were exposed to 100 µM etoposide 
for 1 h, and phosphorylation of p53 on serine 15, 37 and 46 was analyzed by western blotting. (D) Huh7 and HA-PP2Ac cells were exposed to 100 µM etoposide 
for 24 h, and RNA was isolated. The expression of genes was monitored by qPCR. Results are expressed as mean ± SEM from three independent experiments.
Fig. 2. PP2Ac overexpression reduces caspase-9 activation upon etoposide stimulation and promotes fibroblast transformation. (A) Huh7 and HA-PP2Ac cells 
were stimulated with 100 µM etoposide for 1 h, and caspase-9 activity was measured using Caspase-Glo 9 Assay. Results are expressed as mean ± SEM from 
two independent experiments. (B) Huh7 cells or human fibroblasts untransfected or transfected with an HA-PP2Ac coding plasmid were cultured on a semisolid 
culture media for 7 days. Colonies were visualized by light microscopy. Representative pictures of colonies after 7 days of culture on semisolid support are 
shown.
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etoposide-induced phosphorylation of p53 on serine 37 and 46, but 
not on serine 15 (Figure 3A), and consequently a significantly higher 
expression of Noxa and PUMA, two direct p53-induced apoptotic 
genes (Figure 3B).
PP2Ac overexpression in B6HCV mice impairs Etopophos-
mediated p53 phosphorylation, reduces DEN-induced p53 target 
gene expression and increases DEN-induced HCC formation
To assess the in vivo relevance of our findings, we injected B6HCV 
and C57BL6 control mice with Etopophos. We used B6HCV mice 
because no transgenic mouse model with direct PP2Ac overexpres-
sion exists, but B6HCV mice consistently showed a significant over-
expression of PP2Ac in the liver (4). Upon Etopophos injection, we 
observed phosphorylation of p53 on serine 18 (homologue to serine 
15 in human) in liver homogenates of C57BL6 mice. This phospho-
rylation is impaired in B6HCV mice (Figure 4A). We were not able 
to investigate phosphorylation on serine 46 and 37 because no anti-
bodies against these phosphorylation sites are available for mouse. 
We investigated further the effect of PP2A on p53-mediated apopto-
sis by analyzing caspase-9 cleavage upon injection with microcystin 
LR, a DNA damage compound. As shown in Supplementary Figure 
S3, available at Carcinogenesis Online, a clear reduction of cleaved 
caspase-9 in B6HCV mice can be observed, suggesting a reduction of 
apoptosis in these transgenic animals.
Carcinogenesis is a complex process involving alterations of DNA 
damage repair and apoptosis (28). We have shown previously that 
PP2Ac overexpression renders cells more susceptible to DNA damage 
and impairs DNA repair (7). In the present paper, we report an 
impairment of apoptosis. We, therefore, investigated if B6HCV mice 
that overexpress PP2Ac are more susceptible to HCC. B6HCV and 
C57BL6 mice were injected with DEN, a carcinogen known to induce 
liver tumors in mice. Mice were euthanized 40 weeks after a single 
injection of a low dose of DEN. We observed a reduction of Noxa and 
PUMA, two direct p53 target genes (Figure 5A) in non-tumoral liver 
tissue obtained from B6HCV mice, suggesting a diminution of p53 
proapoptotic function. We, therefore, analyzed cleaved caspase-3 in 
B6HCV and in C57BL6 mice. Our data show a reduction of caspase-3 
cleavage in B6HCV mice compared with control animals, suggesting 
a diminution of DEN-induced apoptosis in the transgenic mice 
(Figure 5B). We confirmed these results by staining cleaved caspase-3 
on liver sections. As shown in Figure 5C, C57BL6 mice showed more 
caspase-3 cleavage than B6HCV mice. Furthermore, we observed 
pronounced chromatin condensation in control animals compared 
Fig. 3. PP2Ac silencing alters p53 phosphorylation and p53-induced proapoptotic genes expression. (A) Control-scrambled and short-hairpin small interfering 
RNA PP2Ac cells were treated with 100 µM etoposide for 1 h, and phosphorylation on p53 was monitored by western blotting. A representative blot from at least 
two independent experiments is shown. (B) Cells were treated with 100 µM etoposide for 24 h, and the expression of the genes was quantified by quantitative 
PCR. Results are expressed as mean ± SEM from three independent experiments.
Fig. 4. PP2Ac overexpression in HCV transgenic mice impairs p53 
phosphorylation upon Etopophos injection. Eight-week-old C57BL6 (n = 2) 
and B6HCV (n = 2) mice were injected with Etopophos and killed 2 h later. 
Liver homogenates were analyzed by western blotting with antibodies to 
phosphoserine 18 on p53, p53, actin, HCV core and PP2Ac.
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Fig. 5. PP2Ac overexpression in HCV transgenic mice reduces p53 proapoptotic function and enhances liver tumor formation upon DEN injection. (A) C57BL6 
and B6HCV mice were injected intraperitoneally with DEN at 5 µg/g of body weight. Animals were killed 40 weeks after DEN administration. The expression 
of Noxa and PUMA was quantified by quantitative PCR and expressed relative to RPL19. Results are expressed as mean ± SEM from 22 control animals and 17 
transgenic mice, and statistical analysis was performed using Student’s t-test. (B) Cleaved caspase-3 was detected by immunoblotting in liver homogenates from 
mice injected with DEN. A representative blot is shown. (C) Detection of caspase-3 cleavage by immunofluorescence from mouse liver sections. A representative 
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with transgenic mice, demonstrating more apoptosis in C57BL6 
mice (Figure  5C). We counted more liver tumors in B6HCV mice 
than in C57BL6 mice (Figure 5D). These liver tumors were bigger 
in B6HCV mice than in control mice (Figure 5D and 5E). The body 
weight and the liver weight remained unchanged between control 
and transgenic mice (Figure 5D). Histology of the liver tumors did 
not show any significant difference between B6HCV and C57BL6 
mice (Figure 5E). In both groups, the tumors were characterized by 
loss of the normal lobular architecture and displayed irregular growth 
pattern. They were sharply demarcated from the surrounding liver 
parenchyma that was often compressed. Moreover, focal areas of 
cellular atypia characterized by slight pleomorphic nuclei, coarsely 
clumped chromatin, large nucleoli and cytoplasmic basophilia were 
also present. All these histological features are consistent with murine 
hepatocellular adenomas, which are typically found after a single 
DEN injection (29).
PP2Ac is upregulated in tumorous liver biopsies and negatively 
correlated with p53 proapoptotic gene expression
In order to assess the correlation between PP2Ac expression and p53 
proapoptotic gene expression in humans, we performed a quantita-
tive PCR analysis using paired liver biopsies from HCC and from tis-
sue outside the tumors collected from patients with and without CHC 
(Table I). Indeed, analysis of PP2Ac expression revealed a higher 
expression of PP2Ac in malignant tissue than in non-tumorous sur-
rounding tissue both from non-CHC patients (Figure 6A). We then 
Table I.  Clinical characteristics of HCC liver biopsies
No. Code Age Sex Fibrosis 
grade
HCV/HBV infection Alcohol 
abuse
Focality Pathology Edmonson 
grade
1 A1 63 M F4 No virus Yes Multifocal Trabecular, pseudoglandular, 
inflammation
III
2 A12 69 M F0 No virus No Singular Trabecular, focally necrotic II
3 A37 68 M F4 No virus Yes Singular Trabecular-sinusoidal II
4 A255 79 F F3–F4 HBV No Singular Trabecular II
5 A268 63 M F4 No virus Yes Multifocal Trabecular, hyaline globules II
6 A286 63 M F3 No virus – Singular Trabecular, lamellar fibrosis, 
steatosis
II
7 A367 64 M F3–F4 No virus Yes Singular Trabecular, focally clear cell II
8 A442 75 M F4 No virus Yes Multifocal NA II
9 A722 80 F F1 HCV GT NA No Singular Trabecular II
10 A724 60 M F4 HBV No Multifocal Mixed hepatocholangiocarcinoma III
11 A824 62 M F3–F4 HBV Yes Singular Mixed hepatocholangiocarcinoma III
12 A829c 30 M F1–F2 HBV No Singular Stem cell-like, mixed 
hepatocholangiocarcinoma
IV





14 A879 67 M F3–F4 HBV – Multifocal Trabecular II
15 A896 71 M F4 No virus Yes Multifocal Trabecular III
16 A911 52 M F4 HCV GT NA – NA Pseudoglandular II
17 A915 85 M F0–F1 No virus No Singular Trabecular, pseudoglandular II
18 A941 48 M F4 HCV GT 1a (6.25 log10) Yes Multifocal Trabecular, partly necrotic III
19 A969 68 M F4 No virus No Singular Trabecular II
20 B21 75 M F4 No virus Yes Singular Trabecular, Mallory bodies, 
granulomatous inflammation
II–III
21 B39 59 M F4 No virus Yes Singular Trabecular, inflammation III
22 B62 58 F F4 HBV – Singular Trabecular II (focally I)
23 B77 59 M F4 No virus Yes Multifocal Solid III
24 B156 78 M F4 No virus Yes Multifocal Trabecular, microacinary II
25 B214a 75 M F3 No virus Yes Two foci Solid II
26 B277 62 M F4 HCV GT 1b (4.79 log10) – Singular Solid, necrosis, inflammation III
27 B313 69 F F4 HBV No Two foci Trabecular, inflammation II
28 B322 65 M F4 No virus Yes Two foci Trabecular, inflammation II
29 B326 54 M F4 HCV GT 1b (5.18 log10) Yes Singular Trabecular III
30 B370 60 M F0 No virus Yes Multifocal Trabecular, focally clear cell II
31 B399 52 M F4 HCV GT 1b (4.23 log10) Yes Multifocal Trabecular III
32 B410 76 M F4 No virus Yes Multifocal Trabecular II
33 B442 57 M F4 No virus Yes Multifocal Trabecular, lamellary fibrosis III
34 B459 50 M F4 HBV No Singular Trabecular II
35 B540 63 M F4 No virus Yes Multifocal Trabecular, inflammation, 
steatosis
II
36 B568 85 M NA No virus Yes Three foci Trabecular, partly necrotic II
37 B592 76 M F4 No virus Yes Multifocal, 
diffuse
Trabecular, hyaline globules II
38 B597 57 M F4 No virus Yes Singular Trabecular II
HBV, hepatitis B virus.
result is shown. Right panel shows enlargement of delimitated areas. Chromatin condensation, an apoptotic nuclear feature, is clearly visible in C57BL6 mouse 
that received DEN. (D) Body weight, liver weight, number and size of macroscopic lesions recognizable from the outside were measured 40 weeks after DEN 
injection. Results are expressed as mean ± SEM from 22 control mice and 17 HCV transgenic animals. (E) Macroscopic and microscopic examples of liver 
tumors from C57BL6 and B6HCV mice 40 weeks after receiving 5 µg/g of DEN. Liver tumors were easily recognizable as spherical, light-brown nodules by 





confirmed these data on the protein level and showed that PP2Ac 
protein is more significantly upregulated in tumorous tissues than in 
non-tumoral surrounding tissues both from non-CHC-related HCC 
samples (Figure 6B). This upregulation was not visible in CHC-related 
HCC tissues because of the elevated expression level of PP2Ac in 
non-tumorous liver parenchyma in patients with CHC compared with 
control samples from patients with other liver diseases (30). Because 
of this increased expression of PP2Ac in non-tumorous tissues, we 
excluded CHC patients from the overall analysis. We then analyzed 
the expression of Noxa and PUMA, two p53-dependent genes that 
were altered by PP2A upregulation in vitro. Our data showed no sig-
nificant difference of Noxa expression between tumorous and non-
tumorous samples (Figure 6D). However, we observed a significant 
reduction of PUMA expression in malignant versus non-tumorous 
tissue (Figure 6C).
Discussion
We have reported previously that HCV-induced PP2Ac upregulation 
impairs epigenetic changes on histone H4 and inhibits DNA damage 
repair machinery (4,7). In the present study, we show that PP2Ac 
also inhibits p53. As a consequence, B6HCV mice that overexpress 
PP2Ac in the liver have an increased susceptibility for HCC. We 
realize that our HCV-mediated PP2Ac overexpression mouse is an 
indirect in vivo model to experimentally explore the consequences of 
PP2Ac overexpression. A transgenic mouse model of PP2Ac overex-
pression would be preferable, but no such animal model is available. 
However, given our findings in cells with overexpression and silenc-
ing of PP2Ac, and the results in regard to serine phosphorylation of 
p53 and p53 target gene induction in the B6HCV animal model, we 
conclude that PP2A-induced dysregulation of p53 is an important 
mechanism of HCC carcinogenesis. Interestingly, in several experi-
mental systems, PP2A has tumor suppressor functions (31). In our 
model, PP2A seems to predispose cells to transformation by altering 
p53 functions. There have been other reports of the procarcinogenic 
role of PP2A, notably in testicular germ cell tumors and for T-cell 
leukemia cells (32,33).
DEN is a well-known liver carcinogen (34). DEN is usually 
injected at doses 50–200 µg/g of body weight to rats (35–37) and 
at doses 75–90 µg/g of body weight to mice (38,39) to induce liver 
tumors. Some studies have used DEN at 5 µg/g of body weight 
associated with a second injection of a liver tumor promoter, 2 
weeks after DEN administration (40). At the dosages of 75–90 
µg/g of body weight, mice develop liver tumors by 40 weeks. 
Therefore, in order to test if HCV-mediated PP2Ac overexpres-
sion could predispose mice to liver tumors, we have deliberately 
injected a single low dose of 5 µg/g of DEN. Our results show that 
B6HCV had a higher incidence of liver tumor formation than the 
control mice, presumably caused by an initial higher expression 
of PP2Ac that facilitates DNA damage and inhibits p53-mediated 
apoptosis.
The proapoptotic function of the tumor suppressor p53 is con-
trolled by numerous posttranslational modifications on several resi-
dues. We have focused on some specific and characterized residues. 
It has been shown that PP2A inhibition or knocking down using 
pharmacological inhibitors or small interfering RNA, respectively, 
enhanced phosphorylation on serine 46 and induced apoptosis (41). 
Additionally, using PP2A inhibitors, it has been demonstrated that 
PP2A dephosphorylates serine 37 and negatively controls p53 tran-
scriptional activity (19). In line with these previous observations, we 
show that PP2Ac overexpression impairs phosphorylation of p53 on 
serine 37 and 46 but not on serine 15. Our observation that etoposide-
induced serine 15 phosphorylation is reduced only in UHCV57.3 
cells is intriguing. However, it has been reported previously that 
phosphorylation on serine 15 can substantially be suppressed by a 
high expression of HCV core in HepG2 cells (42). Therefore, we 
hypothesize that the impairment of phosphorylation on serine 15 
might be caused by a high expression of the core in these HCV-
inducible cells independently of PP2Ac upregulation. Similarly, the 
reduction of serine 18 phosphorylation, a homolog of serine 15 in 
human, in HCV transgenic mice was presumably due to an elevated 
expression of HCV core in these animals. Surprisingly, we did not 
observe an impaired serine 15 phosphorylation in HCV-infected 
Huh7 cells. The discrepancy could be caused by a more restricted 
subcellular location or a lower expression level of HCV core protein 
during HCV replication in the infectious cell culture system com-
pared with UHCV57.3 cells. Further analyses are required to clarify 
this issue.
It has been shown that p53 serine residues can be phosphoryl-
ated by a number of kinases, amongst them ATM, DNA-PK and 
p38MAPK (41,43,44). Therefore, PP2A might decrease serine 37 
and 46 phosphorylation by regulating one or more of these kinases. 
However, the specific dephosphorylation of p53 serine 37 and 46 
observed in the in vitro dephosphorylation assays (Supplementary 
Figure S2, available at Carcinogenesis Online) provides evidence 
for a direct mechanism where the phosphatase enzymatic activ-
ity of PP2A is responsible for the dephosphorylation of serine 37 
and 46.
We have reported previously that PP2A catalytic subunit is 
overexpressed in liver biopsies from patients chronically infected with 
Fig. 6. PP2Ac is highly expressed in malignant tissues from non-CHC-
related HCC and negatively correlates with PUMA expression. Quantitative 
reverse transcription–PCR was performed on paired liver biopsies (CT = 
non-malignant surrounding tissues; TU = malignant tissues) from CHC  
(n = 7) and non-CHC-derived HCC (n = 31). (A) PP2Ac expression 
level was determined in CHC and non-CHC samples. (B) PP2Ac protein 
expression level was evaluated by immunoblotting from non-CHC samples. 
(C) PUMA and (D) Noxa expression levels were measured in non-CHC 
samples. Results are shown as box plots, and statistical analysis was 
performed using Mann–Whitney’s test.
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HCV. Because our in vitro and in vivo data demonstrated that PP2A 
overexpression leads to impairment of p53-induced apoptosis and 
correlates with more HCC foci formation in the presence of mutagenic 
agents, we expected to measure a significantly higher expression of 
PP2Ac in tumorous biopsies than in non-tumorous biopsies from 
CHC-related HCC. Because of the elevated expression level of PP2Ac 
in non-tumorous liver parenchyma in patients with CHC compared 
with control samples from patients with other liver diseases (30), 
we were not able to measure a difference in the expression level 
between non-tumorous versus tumorous tissues. However, analysis 
of paired biopsies from non-CHC-derived HCC clearly showed an 
overexpression of PP2Ac in tumorous versus non-tumorous samples. 
The transcription factor, cyclic adenosine monophosphate response 
element-binding protein (CREB), is overexpressed or activated in 
several malignancies (45). For instance, total and active CREB is 
enhanced in HCC samples versus normal liver samples in a rat model of 
HCC (46). Furthermore, we have reported that endoplasmic reticulum 
stress response induces PP2Ac upregulation via CREB activation (5). 
Thus, we believe that the increased expression of PP2Ac in tumorous 
tissues from non-CHC related HCC is presumably caused by CREB 
transcriptional activity. Taken together, our data show an elevated 
expression of PP2Ac in tumorous samples and a negative correlation 
with PUMA, suggesting that PP2Ac upregulation provides favorable 
conditions for carcinogenesis.
In conclusion, we demonstrated that PP2Ac overexpression par-
ticipates in tumor establishment and maintenance by altering the 
apoptotic cell death program. Importantly, this is the first report that 
associates HCV-induced PP2Ac overexpression with liver tumors.
Supplementary material
Supplementary Figures S1–S3 can be found at http://carcin. 
oxfordjournals.org/
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